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ABSTRACT 
The present study was designed to investigate the presence of mannose binding lectin (ManBL) in the sera and tissue samples of 
patients with tumoral (benign & malignant) kidney in addition to patients with non tumoral kidney affection, in order to establish 
the possibility of using serum and tissue ManBL test for diagnosis and epidemiological testing of kidney cancers. Participants of 
the present study were 96 patients at the age range 12-80 years; they were attending by different hospitals in Najaf (basically) and 
Karbala, and 46 healthy individuals within the same age range of the studying patients groups. Specific hemagglutination activity 
levels were revealed a significant increased (p < 0.001) in the sera and tissues of the patients with the malignant tumors specimens 
in comparison to that of pathological controls and healthy individuals. Serum and tissue hemagglutination activity levels were 
significantly higher (p < 0.001) in patients with metastatic disease compared with patients with localized tumors. While, the levels 
of the hemagglutination activity were approximate at patients with the end malignant kidney tumors stages. Upon electrophoresis 
of the study samples, the results reflected presence of changes in some proteins and glycoproteins bands presents in these samples. 
Using hydrophobic affinity chromatography,  ManBLs  were purified from  sera of  malignant, benign kidney tumors and  non 
tumoral kidney diseases in addition to healthy individuals groups. The purified lectins were found to be glycoprotein with 77.45 
KD as an approximate  molecular  weight and its sugar content  was equal to13.5%. The  maximum concentration of purified 
ManBL was found at patients with malignant kidney tumors.The results revealed that the highest hemagglutination activity of 
purified ManBL occurred with O
+ RBCs, at pH 7.4, and 37˚C. ManBL (regardless of its origin) lost the hemagglutination activity, 
completely, in the presence of EDTA. A result that indicates that the present purified the human ManBLs is a calcium dependent 
type. 
 
1. INTRODUCTION 
Lectins, simply; are ubiquitous proteins or glycoproteins that are probably present in all eukaryotic cells
1-6, and many 
bacterial species
7, 8, as well as in some viruses
9, 10. Theyare capable to bind mono - and oligosaccharides with high 
affinity
11,  12,  and  usually  agglutinate  cells  or  precipitate  polysaccharides  and  glycoconjugates  specifically  and 
reversibly
13,  11. The binding involves hydrophobic interactions as well as hydrogen bonds
14. Lectin specificity for 
individual sugars or groups of sugars makes them powerful tools for detecting changes in the carbohydrate structure of 
the glycoproteins
15, 16.  
Early observations of cancer patients who had fully recovered from an acute bacterial infection suggested that innate 
immunity has anti tumor activity. Complement activation may lead to the liberation of pro-inflammatory factors and 
the activation of inflammatory cells, which may have pro-carcinogenic effects. Activation of complement by mannose 
binding lectin (ManBL) is crucial for innate immune .This relationship has been revealed by analysis of common 
single  nucleotide  polymorphisms  (SNPs)  in  the  ManBL2  gene,  which  encodes  ManBL.  The  frequency  of  SNP-
determined ManBL deficiency is significantly higher in patients presenting with various infections and autoimmune 
disorders than it is in the general population, indicating the importance of ManBL in host defence. Thus, additional 
evidence suggests that ManBL function contributes to human cancer risk
17, 18.  
Renal cancer is the third most common malignancy of the genitourinary system
19, and accounts for 3% of adult 
malignancies  globally
20.  Limited  early  warning  signs  result  in  late  recognition  with  metastases  present  in 
approximately one third of patients at the time of diagnosis
21, with 210,000 new cases per year and more than 100,000 
deaths occurring worldwide annually. The male to female ratio is 1.5:1, and the disease usually occurs in the sixth and 
seventh  decades  of  life
22.  RCCs  are  highly  vascularized  tumors,  which  may  explain  the  30-40%  prevalence  of 
metastatic disease at initial diagnosis
23, 24, when systemic therapies are then necessary. In this group of patients, one-
year survival rate are ~25%, illustrating the limited role of both chemotherapy and radiotherapy in the management of 
advanced stages of RCC
25.  
 
2. EXPERIMENTAL 
 
2.1 Patient and Control Individuals 
The present study involved 96 patients (55 cases with malignant kidney tumors, 23 cases with benign kidney tumors, 
and 18 cases with non tumoral kidney diseases) with the age range 10-80 years, in addition to 46 healthy individuals, 
at the same age range. 
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2.2 Isolation of Crude Lectins from Serum and Tissue Specimens 
Ten millilitres of venous blood samples were collected from patients and the control groups. Samples were allowed to 
clot at room temperature, centrifuged at 3000 xg for 5 minutes, and then sera were collected and stored at –15˚C. 
Different  tissue  specimens  were  removed  from  the  patients  by  surgery  carried  out  by  specialist  during  surgical 
intervention, washed many times with 0.9% (w / v) NaCl, and stored immediately at  –15˚C. 
The frozen tissue (1g); after cutting into slices was homogenated by manual homogenizer in 3 ml of Tris-HCl buffer 
solution (20 mM, pH 8) on ice bath. The suspension was centrifuged and the supernatant was used for lectin isolation.  
For isolation of serum and tissue crude lectins, 1 volume of serum was mixed with 2.5 volumes of petroleum ether, 
while; 2 volume of the homogenate supernatant were mixed with 3 ml of petroleum ether for defatting. The mixtures 
were shacked strongly, then, centrifuged at 3000 xg for 5 minutes. The organic phase was neglected and defatted 
serum and homogenate supernatant were stored at –15˚C to be used for determination of the hemagglutination activity. 
 
2.3 Preparation of Standard Ttrypsinized Erythrocyte Suspension for Hemagglutination Test 
Human blood group O
+ erythrocytes were collected from the local blood bank in Al-Sadder Teaching Hospital in 
Najaf in Iraq. Blood was centrifuged at 3000 xg for 5 minutes, the sera were discarded. The erythrocytes were washed 
with saline solution (5 ml saline: 1 ml packed erythrocytes), then were suspended in phosphate buffer saline solution 
(pH 7.4), and diluted with the same buffer to give an absorbance of 2 ml at 620 nm. 
One  part  of  trypsin  solution  (1%)  was  added  to  10  parts  of  the  final  erythrocytes  suspension.  the  mixture  was 
incubated at 37˚C for 1 hour, and then centrifuged at 5000 xg for 5 minutes. The trypsinized erythrocytes mixture was 
washed 3 – 5 times with saline solution to remove trypsin traces. Saline solution was added, until the absorbance of 
the erythrocyte suspension was 1.4 at 620 nm. 
 
2.4 Protein Determination 
Total proteins in the studied samples were estimated using Bradford method
26, and bovine serum albumin was used as 
a standard protein.    
 
2.5 Determination of Hemagglutination Activity of Crude Serum and Tissue Lectins of Patient and Control 
Groups 
To determine the hemagglutination activity in serum and tissue Lis and Sharon
27 method was used, with essential 
modifications. The procedure involved three tubes, test (T), blank (B), and control (C). A set of control tubes (2 – 4) 
were used in each experiment and the assay was carried out as in the following 
 
Components  Test  Blank  Control 
Diluted serum (1:20) with Tris-HCl buffer (20 Mm, 
pH 8), or Crude tissue lectins preparation 
1 ml 
 
1 ml 
 
- 
 
Trypsinized erythrocyte suspension  2 ml  -  2 ml 
Saline solution  -  2 ml  1ml 
Calcium chloride solution (60 mM)  1 ml  1 ml  1 ml 
T, B, and C tubes were placed in exactly vertical position at 37˚C for 75 min. 
Cells were separated after centrifugation at 3000 xg for 3 minutes, then  re-suspended in the above mentioned buffer by gentle 
shaking, and allowed to stand for another 75 minutes at 37˚C. 
The absorbance of 2 ml of the upper mixtures was measured at 620 nm. 
 
The reduction of optical density (ROD) in the test tube (in crude sera and tissues determination) was measured from 
the following equation: 
 
100
C A
B T A C A
    ROD%   

 
 
Where: 
 
C A  = Optical density of cell suspension in the control tube. 
B T A   = Optical density of cell suspension in the test tube – Optical density of cell suspension in the blank tube. Jasim et al, 2011 
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2.6 Purification of ManBL 
Affinity chromatography technique was applied for the purification of ManBL from patients' with tumoral and non 
tumoral kidney diseases, in addition to healthy individuals. Preparation of the affinity chromatography column was 
carried out according to the instructions of Hermanson
28, and Amersham handbook [Amersham Pharmacia Biotech]. 
 
2.7 Determination of Carbohydrate Content in the Purified ManBL 
Dubois method
29 was followed for determination of carbohydrate amount in the purified ManBL. Where glucose was 
used as a standard sugar. 
 
3. RESULTS AND DISCUSSION 
3.1 Levels of the Specific Hemagglutination Activity in Patients and Control Groups 
 
3.1.1 In Serum 
The optimized conditions of the hemagglutination protocol were used for estimation of individual serum lectin activity 
in the studied groups. It was expressed as specific hemagglutination activity unit (SHU). Fig-1, demonstrates that 52 
patients out of the 55 studied patients of malignant kidney tumors have a hemagglutination activity higher than 6 
SHU, while those of non tumoral kidney diseases and healthy individuals (except one sample in each group) have less 
than 6 SHU. Also those of benign kidney tumors were found to have specific activity less than 6 SHU. These results 
suggest the possibility of using 6 SHU as a cut off value for the specific hemagglutination activity. A result showed 
the possibility of using this parameter as a biomarker for discriminating of patients with malignant kidney tumors 
among those with benign, non tumoral kidney diseases, and healthy individuals.  
 
 
Fig-1: Distribution of the Serum Hemagglutination Activity in Patients of Malignant Kidney Tumors (K1), Benign Kidney 
Tumors (K2), Non Tumoral Kidney Diseases (K3), and Healthy Individuals (H). The symbol – - – - refer to the cut off of 
malignant kidney tumors value 
 
The evaluation of the specific hemagglutination activity in the various groups revealed a significant increase (p < 
0.001) in patients of malignant kidney tumors when compared with those of benign tumors, non tumoral kidney 
diseases,  and  healthy  individuals.  However,  non  significant  variations  were  obtained  when  other  groups  were 
compared together (Table-1). The sensitivity and specificity of serum lectin activity in detection of malignant kidney 
tumors were 94.54 % and 95.65 % respectively. 
 
Table-1: Serum Specific Hemagglutination Activity Levels in Patients of Malignant Kidney (K1) and Benign Kidney (K2) 
Tumors, Non Tumoral Kidney Diseases (K3), and Healthy Individuals (HK1 and HK2) 
Group 
Age (year) 
Mean ± S.D. 
Range 
SHU 
Mean ± S.D. 
Range 
p 
K1 
(55) 
54.93 ± 12.50  
32 – 80  
14.99 ± 6.21  
4.79 – 29.08   0.000** for K1vs K2 
 
0.000** for K1vs K3 
 
0.309 for K2vs K3 
 
0.000** for K1 vsHK1 
 
0.491 for K2vs HK2 
 
0.724 for K3vs HK2 
K2 
(23) 
45.04 ± 15.33  
10 – 66  
3.04  ± 1.31 
1.17 – 6.49 
K3 
(18) 
42.39  ± 16.60 
12 – 68 
4.44  ± 4.27 
0.99 – 20.70 
HK1 
(32) 
47.38 ± 10.92 
32 – 80 
4.27 ± 1.87 
1.09 – 9.09 
HK2 
(43) 
39.77 ± 13.77 
10 – 66 
3.94 ± 1.71 
1.09 – 9.09 
HK2 
(43) 
39.77 ± 13.77 
10 – 66 
3.94 ± 1.71 
1.09 – 9.09 
The mean difference is significant at the 0.001 level. **Refers to significant difference between variables. 
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In the present study, the hemagglutination activity levels in 21 patients with malignant kidney tumors were followed 
up for 72 hours after surgical operation, of the removal of the tumor. The result showed presence of a decrease in their 
serum hemagglutination activities after the removal of the tumors (data not shown). 
 
3.1.2 In Tissue 
Fig-2, shows that patients of malignant kidney tumors (except one case only) have a tissue hemagglutination activity 
level higher than 0.13 SHU, while those of benign kidney tumors and non tumoral kidney diseases were less than 0.13 
SHU. These results suggest that 0.13 SHU could be used as a cutoff value (biomarker) for discriminating, the tissue of 
patients of malignant kidney tumors from other kidney tumoral& none tumoral diseases. 
 
 
Fig-2: Distribution of Tissue Hemagglutination Activity Levels in Patients of Malignant Kidney Tumors (K1), Benign Kidney 
Tumors (K2), and Non Tumoral Kidney Diseases (K3). The symbol – - – - refer to the cut off malignant kidney tumors value. 
 
The evaluation of the SHU in the various kidney groups revealed a significant increase (p < 0.001) in patients of 
malignant kidney tumors when compared with those of benign tumors, and non tumoral kidney diseases, while, non 
significant  difference  was  found  when  the  benign  kidney  tumors  and  non  tumoral  kidney  diseases  groups  were 
compared together (Table-2). 
 
Table-2:Tissue Specific Hemagglutination Activity Levels of Tumoral(Malignant and Benign) and Non Tumoral Kidney Patients 
Patients  Age (year) Mean ± S.D. 
Range 
SHU 
Mean ± S.D. Range 
p 
K1 
(55) 
54.93 ± 12.50 
32 – 80 
0.24 ± 0.08 
0.12 – 0.40 
0.000**for K1vs K2 
 
0.000** for K1vs K3 
 
0.627for K2vs K3 
K2  
(23)  
45.04 ± 15.33 
10 – 66 
0.08 ± 0.02 
0.05 – 0.12 
K3  
(18)  
42.39 ± 16.60 
12 – 68 
0.09 ± 0.02 
0.07 – 0.12 
K1: Malignant Kidney Tumor Patient group, K2: Benign Kidney Tumor Patients and K3: Non Tumoral Kidney Patients. The 
mean difference is significant at the 0.001 level. **Refers to significance between the variables 
 
3.2 Correlation of Serum and Tissue Hemagglutination Activities of kidney patients Groups 
The correlation of lectin contents (specific hemagglutination activity) in serum and tissue from malignant kidney 
tumor patients in addition to pathological tissues (benign tumors and non tumoral kidney tissues) was evaluated using 
the linear regression analysis. Fig-3 A, B, and C, illustrates presence of a significant positive correlation (r = 0.89 at p 
< 0.001) between the specific hemagglutination activity of serum and tissue samples in the cases of malignant kidney 
tumors. While such correlation was not observed in those of benign tumors and non tumoral diseases. 
 
 
Fig-3: Correlation of Serum and Tissue Hemagglutination Levels in Patients of A: Malignant tumors, B: Benign tumors, and C: 
Non Tumoral Kidney Diseases 
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3.3 Implication of Stages of Malignancy in Serum and Tissue Specific Hemagglutination Activity 
In order to verify the changes of the hemagglutination activity with the advancing of malignancy, the patients were 
subdivided according to the stage of the diseases into stage I, II, III, and IV. From the statistical analysis of the 
malignant  kidney  tumors  of  different  stages,  a  positive  correlation  was  observed  between  the  serum  specific 
hemagglutination activity & the malignant tumor progression (r = 0.767 at p < 0.0005) (Fig-4).  
 
 
Fig-4: Correlation of Serum Hemagglutination Activity with Stages of Malignant Kidney Tumors 
 
The mean levels of specific hemagglutination activity in patients of the four stages of malignant kidney tumors are 
illustrated in table 3. Significant elevations (p < 0.001) of the specific hemagglutination activity were observed when 
the data of each two stages (except III and IV) were compared. 
 
Table 3:The Differences in Serum Specific Hemagglutination Activity of Malignant Kidney Tumor Patients According to the 
Stage of the Disease 
Subjects 
Age (year) 
Mean± S.D. 
Range  
SHU 
Mean± S.D.  
Range  
p 
Stage І 
(14) 
49.07 ± 11.94 
32 – 74 
8.03 ± 2.40 
4.79 – 12.80 
 
0.000** For 
(1, 2, 3, 4, and 5) 
 
0.011 for (6) 
Stage П 
(12) 
55.67 ± 13.85 
34 – 79 
12.40 ± 1.21 
10.37 – 14.42 
Stage Ш 
(11) 
53.73 ± 9.71 
43 – 75 
17.58 ± 2.73 
13.87 – 23.47 
Stage ΙV 
(18) 
59.72 ± 12.40 
41 – 80 
20.55 ± 5.57 
7.97 – 29.08 
The mean difference is significant at the 0.001 level. **Refers to significance between the variables. 
1)Stage I vs. Stage II, 2) Stage I vs. Stage III, 3) Stage I vs. Stage IV, 4) Stage II vs. Stage III, 5) Stage II vs. Stage IV 
6) Stage III vs. Stage IV 
 
Fig-5  demonstrates  presence  of  a  significant  (r  =  0.781  at  p  <  0.0005)  positive  correlation  between  tissue 
hemagglutination activity of kidney tumors& the progression of the malignancy.  
 
 
 
Fig-5:Correlation of Tissue Hemagglutination Activity with Stages of Malignant Kidney Tumors 
 
The evaluation of tissue specific hemagglutination activity levels in patients of malignant kidney tumors at different 
stages of the disease demonstrated a trend of gradual rise as malignancies were advanced (Table-4).  
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Table 4: Levels of Tissue Specific Hemagglutination Activity at Different Stages of Malignant Kidney Tumors 
 
Subjects 
 
Age (year) 
Mean± S.D. 
Range 
SHU 
Mean± S.D.  
Range  
p 
Stage І 
(14) 
49.07 ± 11.94 
32 – 74 
0.16 ± 0.03 
0.12 – 0.20 
0.000** for  (2, 3, 4, and5) 
 
0.103 for (1) 
 
0.299 for (6) 
Stage П 
(12) 
55.67 ± 13.85 
34 – 79 
0.19 ± 0.03 
0.14 – 0.25 
Stage Ш 
(11) 
53.73 ± 9.71 
43 – 75 
0.29± 0.50 
0.22 – 0.36 
Stage ΙV 
(18) 
59.72 ± 12.40 
41 – 80 
0.30 ± 0.06 
0.16 – 0.40 
The mean difference is significant at 0.00 The mean difference is significant at 0.001 levels. **Refers to significance between 
variables 
1)Stage I vs. Stage II,2)  Stage I vs. Stage III, 3)Stage I vs. Stage IV, 4)Stage II vs. Stage III, 5) Stage II vs. Stage IV 
6)Stage III vs. Stage IV 
 
3.4 Gender Involvement in Kidney Lectins Hemagglutination Activity Changes 
The effect of gender on the kidney specific hemagglutination activity levels in patients of cancerous tumors, benign 
tumors, and non tumoral kidney subgroups was evaluated. Student's t-test failed to exhibit significant changes among 
male and female patients (Table-5 and 6). 
 
Table-5:Gender Differences of Serum Specific Hemagglutination Activity in Tumoral and non Tumoral Kidney Disease Patients 
and Healthy Individuals 
Type  
 
Gender  
 
Age (year)  
Mean ± S.D.  
Range  
SHU 
Mean ± S.D.  
Range  
p  
 
K1  
(55) 
M  
(36) 
57.31 ± 13.69 
32 – 80 
15.48 ± 6.94 
4.79 – 29.08   
0.259   F  
(19)  
50.79 ± 9.19 
37 – 65 
14.08 ± 4.55 
7.97 – 21.69 
 
K2  
(23) 
M  
(14)  
43.93± 16.73 
10 – 66 
2.40 ± 0.77 
1.17 – 3.59   
0.377   F  
(9)  
47.44 ± 12.28 
25 – 62 
4.04± 1.38 
2.45 – 6.49 
 
K3 
(18) 
M  
11) )  
47.36 ± 11.33 
27 – 62 
3.95 ± 1.23 
2.05 – 6.00   
0.550  F  
(7)  
34.57 ± 21.22 
12 – 68 
5.21 ± 6.92 
0.99– 20.70 
 
H 
(46) 
M  
(21)  
44.24 ± 9.57 
10 -81 
4.69 ± 2.08 
1.09– 9.09   
0.432  F  
(25)  
44.88 ± 17.10 
11– 87 
3.53 ± 1.14 
1.09 – 6.13 
K1: Malignant Kidney Tumor Patient group, K2: Benign Kidney Tumor Patient group, K3: Non Tumoral Kidney Patients, and H: 
total healthy individuals. M: Male, F: Female. The mean difference is significant at 0.001 level 
 
Previously, the source of increased serum lectins in cancer patient was reported to be unclear
30.The significant positive 
correlations of serum and tissue lectins of patients with malignant tumors reported here suggest presence of a direct 
relationship between their lectins levels which means that the malignant tumors are the sources of lectin present   in 
the sera of the malignant patients. 
Increased levels of tissue lectins in malignant tumor specimens may be due to: (1) during malignancy, an increased 
expression of oncogene proteins due to chromosomal translocation, amplification, or mutation that is considered one 
of the main alterations in the cancer cells. Lectin may be one of these proteins. (2) In malignant tumor cells, the loss of 
tumor suppressor gene protein products due to deletion or mutation, may lead to increase the oncogene proteins, where 
lectin  may  be  among  them.  (3)  Genetic  imprinting  errors  and  genetic  instability  leading  to  progressive  loss  of 
regulated  cell  proliferation,  increased  invasiveness,  and  increased  metastatic  potential.  Expression  of  lectins  is 
completely controlled  by the  machinery system  of protein  synthesis. Therefore,  it is  prone for  alteration  during 
malignant  transformation
4.  (4)  The  elevation  in  several  carbohydrates  concentrations  in  malignant  cells  and  the 
aberrant glycosylation of glycoproteins
16 can be considered one of the causes for lectin production.  
In the present study, removal of the tumors, decreased serum hemagglutination activity, thus tumor tissues are 
most likely to produce and secrete lectins in sera. The agglutination test of cancerous tissues showed that lectin was 
found not only on malignant cells but also in macrophages and stromal cells (mainly fibroblasts) near cancer focus, Jasim et al, 2011 
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and the stromal cells immediately adjacent to cancer nests was found to have higher levels of the hemagglutination 
activity in comparison to cells far from the nests. These results suggest that circulating lectins are generated not only 
by tumor cells but also from peritumoral inflammatory cells and stromal cells. 
 
Table-6:Gender Differences of Tissue Specific Hemagglutination Activity in Tumoral and non Tumoral Kidney disease Patients 
Type  
 
Gender  
 
Age (year)  
Mean ± S.D.  
Range  
SHU 
Mean ± S.D.  
Range  
p  
 
K1  
(55) 
M  
(36) 
57.31 ± 13.69 
32 – 80 
0.24 ± 0.08  
0.12 – 0.40  
0.338 
F  
(19)  
50.79 ± 9.19 
37 – 65 
0.23 ± 0.07  
0.12 – 0.35  
 
K2  
(23) 
M  
(14)  
43.93± 16.73 
10 – 66 
0.09 ± 0.05  
0.05 – 0.25  
0.798 
F  
(9)  
47.44 ± 12.28 
25 – 62 
0.09  ± 0.02  
0.06 – 0.12  
 
K3 
(18) 
M  
11) )  
47.36 ± 11.33 
27 – 62 
0.09 ± 0.01  
0.08 – 0.11  
0.948 
F  
(7)  
34.57 ± 21.22 
12 – 68 
0.09 ±0.02  
0.07 – 0.12  
K1:Malignant Kidney Tumor Patient group, K2: Benign Kidney Tumor Patient group, K3: Non Tumoral Kidney Patients, and H: 
total healthy individuals. M: Male, F: Female. The mean difference is significant at 0.001 level 
 
3.5 Purification of Serum Human ManBL 
Hydrophobic affinity chromatography was used for isolation and purification of ManBL from sera of patients with 
malignant  kidney  tumors,  benign  kidney  tumors,  non  tumoral  kidney  diseases,  and  healthy  individuals.  The 
purification  protocol  was  carried  out  by  using  sepharose  6B  column  activated  with  bis-oxirane  (1,  4  – 
Butanedioldiglycidyl ether) (C10H18O4). The chromatograms of the purified ManBLs were demonstrated in figure 3 
(A, B, C, and D). 
 
 
Fig-6: Affinity Chromatogram of ManBL from A: Malignant Kidney Tumor Patients, B: Benign Kidney Tumor Patients, C: Non 
Tumoral Kidney Diseases Patients, and D: Healthy individuals. Using Sepharose 6B // Mannose Column (1.6×1.3) at Flow Rate 
30 ml / hour. The volume of each fraction was 1 ml. Tris Buffer of 20 mM and 7.4 pH contained 60 mM CaCl2, used as a 
Washing Solution. The Elution step was carried out using the Tris Buffer (20 mM, pH 7.4) contained 5 mM EDTA. 
 
The purification folds and the yield of ManBL from malignant kidney tumors, benign kidney tumors, non tumoral 
kidney diseases, and healthy individuals were139 with 26.4, 185 with 24.2 %, 45 with 6.4 %, and 158 with 18.3 %, 
respectively, (Table-7). 
The  analysis  of  PAGE  electrophoresis  pattern  of  purified  lectins  from  patients  and  the  control  group 
highlighted the appearance of ManBL band in sera of patients with malignant kidney tumors, benign kidney tumors, 
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and non tumoral kidney diseases, in addition to the healthy subjects. The band seemed to be identical and independent 
on the source of the sample, suggesting unchanged expression of ManBL during malignant transformation of the 
kidney. Such observation confirmed the results of affinity chromatography of the intended lectin (Fig-7). 
 
Table-7: Results of the Purification Protocol of Lectins from Sera of Patients with Benign Kidney Tumors, Non Tumoral Kidney 
Diseases, and Healthy Individuals 
Purification step 
Total volume (ml) 
and Total protein 
(mg) 
Total activity 
(HU) 
SHU (HA/ mg of 
protein)  Purification (fold)  Yield % 
MKT Serum  3 
45  44.325  0.985  1  100 
ManBL  7 
0.085  11.688  136.862  139  26.4 
BKT Serum  3 
45  4.353  0.097  1  100 
ManBL  7 
0.059  1.054  17.864  185  24.2 
NTKD Serum  3 
45  17.059  0.379  1  100 
ManBL  8 
0.064  1.093  17.078  45  6.4 
HI Serum  3 
45  4.706  0.105  1  100 
ManBL  9 
0.052  0.860  16.539  158  18.3 
The abbreviations: MKT, BKT, NTKD, and HI: Malignant Kidney Tumor, Benign Kidney Tumor, Non Tumoral Kidney 
Diseases, and Healthy Individual sera 
 
 
Fig-7: Conventional Polyacrylamide Gel Electrophoresis (PAGE) 7.5% for Proteins. Tris - glycin buffer (0.075 M, pH 8.9) used 
as the electrodes buffer solution. Prelctrophoresis conditions were 50 mA as a constant current for 30 minutes, with voltage of 15 
v/cm, and at 4ºC.  Electrophoresis was carried out for10 minutes at 20mA, then the process was continued  for 3.5 hours at 4ºC by 
using 40 mA as a constant current and voltage of 15 v/cm. The gel was stained for protein with silver. The crude and purified 
samples that applied were: 
H: crude Healthy Individuals Sera, 1: purified ManBL from Healthy Individuals Sera, NT: crude Non Tumoral Kidney Affections 
Sera, 2: purified ManBL from Non Tumoral Kidney Affections Sera, B: crude Benign Kidney Tumors Sera, 3: purified ManBL 
from Benign Kidney Tumors Sera, M:crude Malignant Kidney Tumors Sera, 4: purified ManBL from Malignant Kidney Tumors 
Sera 
 
The approximate molecular weights of purified ManBLs were determined using conventional PAGE. Five standard 
proteins with known molecular weighs (Lysozyme 13.6 kD, Chemotrypsinogene  25 kD, Ovalbumin  47 kD, Bovine 
Serum Albumin  67 kD, Lactate Dehydrogenase  140 kD)were used. The estimated molecular weight of ManBLs was 
77.45. 
ManBL (the key component of innate immune system) is the first element to recognize microorganisms and 
control infections when adaptive immune response is immature during childhood or when it is compromised by 
immunosuppressive drugs
31, 17.Exon 1 of the ManBL2gene, which located on chromosome 10, contains 3 functional 
single nucleotide polymorphism at codons 52-54 and 57 referred to variant alleles of D, B and C respectively. The 
impairment  of  polymerization  causes  low  serum  levels  or  impaired  ManBL  function.  Most  ManBL  deficient 
individuals are apparently healthy, because they have alternative mechanisms for antimicrobial protection. However, 
ManBL  deficiency  can  become  a  strong  risk  factor  of  developing  infectious  diseases  in  immunocompromised 
individuals  such  as  organ  transplant  recipients
32.  Clinically  serum  ManBL  was  suggested  a  double-edged  sword 
– 
+  
M   B   N  H  1  2  3  4 
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function, meaning that low serum ManBL levels are indicative of increased risk of infections
33,  34, whereas;  high 
serum ManBL levels is associated with transplant rejection
35,  36, with advanced renal failure predicting all-cause 
mortality
32, and with increased cell invasiveness of primary tumors to distant sites
4, 37.  
 
3.6 ManBL Activity toward Various Human Blood Groups 
To examine the sensitivity of purified ManBLs in the agglutination reactions, blood of A
+, B
+, and O
+ groups were 
used as the source of the erythrocyte samples. O
+ RBCs were indicated to exhibit the maximal agglutination, among 
the evaluated blood groups. This finding could be explained by differences in glycosylation of the surface proteins of 
red blood cells
38.Several studies tested the effect of blood sources on the hemagglutination process of purified lectins 
from various sources
39-41; the result of the present study agreed with some and disagreed with the others. 
 
3.7 Inhibition of ManBL(s) Activity by EDTA 
The hemagglutination process was carried out for the purified ManBLs using human O
+ red blood cells trypsinized 
suspension in the presence of EDTA. ManBL (regardless of its origin) lost the hemagglutination activity, completely, 
in the presence of 1×10
-5 M EDTA. 
 
3.8 Relevance of ManBL Activity with pH Changes 
The effect of pH on the activity of the four purified ManBLs was investigated. Fig-8 points out that maximal lectin 
activity was achieved at pH 7.4 regardless to the source of the examined ManBL, while the purified lectins were 
sensitive to acidic (pH 3) and to basic (pH 12) conditions, under which the activities were completely lost. 
 
 
Fig-8: Effect of the pH on Purified ManBLs Hemagglutination Activity 
 
3.9 Thermal Stability of ManBL Activity 
To explore the effect of temperature on the hemagglutination activity of purified ManBLs, they were incubated at 
various temperatures (0
°C, 30
°C, 40
°C, 50
°C, 60
°C, 80
°C, and 100
°C) for 1 hour; the mixtures were cooled until room 
temperature. The hemagglutination activity was carried out at 30
°C
42.Thermal stability results revealed that purified 
lectins remained stable below 40ºC for one  hour with no loss of hemagglutination activity, while; they loss about 40% 
of their hemagglutination activity at 50 ºC. Lectin activity disappeared when the denaturation was carried out at more 
than 60 ºC (Fig-9). 
 
 
Fig-9: Thermal Denaturation of Purified ManBLs Hemagglutination Activity 
 
The influence of temperature on the hemagglutination activity of purified ManBLs was also evaluated through the 
incubation of purified ManBLs with erythrocyte suspension at 0, 32, 37, 45, 60, and 75˚C. 37˚C seems to be more 
suitable among the examined temperatures for the agglutination process of purified ManBLs (Fig-10). 
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Fig-10: Temperature Effect on the Purified ManBLs Hemagglutination Activity 
 
3.10 The Carbohydrate Content in Purified Lectins 
Total carbohydrate content was found to be 13.5 % from the purified ManBL.  
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